Tag:
Amyvid
Latest Headlines
Latest Headlines
EU signs off on Lilly's Alzheimer's imaging agent
While Eli Lilly struggles with development of its therapy for treating Alzheimer's disease, its diagnostic imaging agent for helping diagnose, or rule out, the condition has gotten another approval, this time in Europe.
EU signs off on Lilly's Amyvid, its diagnostic test for Alzheimer's
While Eli Lilly struggles with development of its therapy for treating Alzheimer's disease, its diagnostic imaging agent for helping diagnose, or rule out, the condition has gotten another approval, this time in Europe.
Lilly on verge of EU approval for brain plaque diagnostic tool
Eli Lilly ($LLY) is on the verge of gaining approval in the European Union to use its radioactive diagnostic agent Amyvid as a tool to detect Alzheimer's related brain plaque buildup, 6months after U.S. regulators granted a similar approval.
Piramal lays claim to a late-stage imaging rival for Lilly's Alzheimer's agent
Piramal wasn't saying just how much it paid for the portfolio, but rather breezily claimed that the market for such Alzheimer's imaging agents could amount to $1.5 billion.
FDA approves Lilly's brain plaque diagnostic tool
Eli Lilly ($LLY) failed last year to gain the FDA's approval to use its radioactive diagnostic agent Amyvid for possible Alzheimer's patients. The second time around, it has finally obtained a positive regulatory sign-off, but for a more general indication.
Lilly gains FDA approval for its controversial brain plaque test
Late on Friday, Eli Lilly put out the word that the FDA had approved its brain dye--Amyvid--for use in ruling out Alzheimer's.
Public Citizen: Lilly study excluded key data on Alzheimer's imaging agent
Public Citizen is charging that Eli Lilly purposefully withheld data which demonstrated the unreliability of Amyvid , its experimental new imaging drug for Alzheimer's, when it submitted a study to
FDA rejects Lilly, Avid Alzheimer's test dye
Earlier this month, Eli Lilly ( $LLY ) CEO John Lechleiter ( photo ) predicted the FDA would approve Amyvid , a new molecular imaging agent that could revolutionize Alzheimer's diagnosis by detecting the
Lilly's Lechleiter predicts Amyvid OK, promises R&D successes
Eli Lilly ( $LLY ) CEO John Lechleiter hit some familiar notes in a speech to a Japanese business group, urging a more predictable regulatory and pricing environment to encourage R&D innovation.
FDA panel rejects Lilly's Amyvid app, but sees how it can work
A large majority of an FDA panel assembled to review the case for Eli Lilly's Amyvid (florbetapir) concluded that the imaging chemical for Alzheimer's isn't quite ready for approval. But if the
